Skip to main content
. 2024 Jan 18;6(4):100999. doi: 10.1016/j.jhepr.2023.100999

Fig. 2.

Fig. 2

Individual patient HBV DNA during the off-treatment phase in patients from study 211.

HBV DNA levels in (A) patients who were HBeAg-positive and (B) patients who were HBeAg-negative during the off-treatment phase in study 211. Parent study designation as well as treatment received during the parent studies are shown. No patients remained <LLOQ of 20 IU/ml (1.3 log10 IU/ml) off treatment. LLOQ, lower limit of quantification; PBO, placebo, VBR, vebicorvir.